以色列 - 希伯来文 - Ministry of Health

novartis israel ltd - ciclosporin - קפסולות - ciclosporin 50 mg - cyclosporin - cyclosporin - prophylaxis of organ rejection in kidney liver heart allogenic transplants in conjunction with corticosteroids. may also be used in the treatment of chronic rejection in patients previously treated with other immuno-suppressive agents. bone marrow transplantation. endogenous uveitis. severe psoriasis above age 16 that did not respond to other treatment. atopic dermatitis in adults only up to 8 weeks for severe cases in which conventional therapy is ineffective or inappropriate. rheumatoid arthritis: severe cases in which standard treatments are ineffective or inappropriate. nephrotic syndrom type mcd (minimal change disease) in cases where conventional therapy has failed.

以色列 - 希伯来文 - Ministry of Health

novartis israel ltd - ciclosporin - קפסולות - ciclosporin 100 mg - cyclosporin - cyclosporin - prophylaxis of organ rejection in kidney liver heart allogenic transplants in conjunction with corticosteroids. may also be used in the treatment of chronic rejection in patients previously treated with other immuno-suppressive agents. bone marrow transplantation. endogenous uveitis. severe psoriasis above age 16 that did not respond to other treatment. atopic dermatitis in adults only up to 8 weeks for severe cases in which conventional therapy is ineffective or inappropriate. rheumatoid arthritis: severe cases in which standard treatments are ineffective or inappropriate. nephrotic syndrom type mcd (minimal change disease) in cases where conventional therapy has failed.

以色列 - 希伯来文 - Ministry of Health

pfizer pharmaceuticals israel ltd - sirolimus - תמיסה (פומי) - sirolimus 1 mg/ml - sirolimus - sirolimus - rapamune is indicated for the prophylaxis of organ rejection in adult patients at low to moderate immunological risk receiving a renal transplant. it is recommended that rapamune be used initially in combination with cyclosporine microemulsion and corticosteroids for 2 to 3 months. rapamune may be continued as maintenance therapy with corticosteroids only if cyclosporine can be progressively discontinued.

以色列 - 希伯来文 - Ministry of Health

abic marketing ltd, israel - fentanyl as citrate - טבליות דחוסות על מקל - fentanyl as citrate 200 mcg/dose - fentanyl - fentanyl - actiq is indicated only for the management of breakthrough cancer pain in patients 16 and older with malignancies who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.

以色列 - 希伯来文 - Ministry of Health

abic marketing ltd, israel - fentanyl as citrate - טבליות דחוסות על מקל - fentanyl as citrate 600 mcg/dose - fentanyl - fentanyl - actiq is indicated only for the management of breakthrough cancer pain in patients 16 and older with malignancies who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.

以色列 - 希伯来文 - Ministry of Health

abic marketing ltd, israel - fentanyl as citrate - טבליות דחוסות על מקל - fentanyl as citrate 1200 mcg/dose - fentanyl - fentanyl - actiq is indicated only for the management of breakthrough cancer pain in patients 16 and older with malignancies who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.

以色列 - 希伯来文 - Ministry of Health

inovamed pharma ltd, israel - carbidopa; entacapone; levodopa - טבליות מצופות פילם - levodopa 100 mg; carbidopa 25 mg; entacapone 200 mg - levodopa - levodopa - treatment of patients with parkinson's disease and end-of-dose motor fluctuations not stabilised on levodopa/dopa decarboxylase (ddc) inhibitor treatment.

以色列 - 希伯来文 - Ministry of Health

inovamed pharma ltd, israel - carbidopa; entacapone; levodopa - טבליות מצופות פילם - levodopa 50 mg; carbidopa 12.5 mg; entacapone 200 mg - levodopa and decarboxylase inhibitor - levodopa and decarboxylase inhibitor - treatment of patients with parkinson's disease and end-of-dose motor fluctuations not stabilised on levodopa/dopa decarboxylase (ddc) inhibitor treatment.

以色列 - 希伯来文 - Ministry of Health

eli lilly israel ltd - olanzapine 210 mg - powder for suspension for injection - olanzapine - zypadhera is indicated for the treatment of schizophrenia.the use of zypadhera is limited to patients who have been diagnosed as non-compliant regarding taking prescribed medicines and as a consequence are prone to outbursts of psychotic episodes .zypadhera is not to be used in patients whose condition is adequately controlled with oral zyprexa .zypadhera is available only through a restricted program which will be conducted according to zypadhera eu risk management plan.for a patient to receive treatment, the prescribers , injection administrators, pharmacists and patients must all be trained on the appropriate elements of the zypadhera risk management plan. the zypadhera risk management plan has been developed to enable the safe use of zypadhera in patients, including the management of those patients who develop post-injection delirium and sedation syndrome. in addition to mandating label language around this risk, this plan includes education and training activities to the following target audience as appr

以色列 - 希伯来文 - Ministry of Health

eli lilly israel ltd - olanzapine 300 mg - powder for suspension for injection - olanzapine - zypadhera is indicated for the treatment of schizophrenia.the use of zypadhera is limited to patients who have been diagnosed as non-compliant regarding taking prescribed medicines and as a consequence are prone to outbursts of psychotic episodes .zypadhera is not to be used in patients whose condition is adequately controlled with oral zyprexa .zypadhera is available only through a restricted program which will be conducted according to zypadhera eu risk management plan.for a patient to receive treatment, the prescribers , injection administrators, pharmacists and patients must all be trained on the appropriate elements of the zypadhera risk management plan. the zypadhera risk management plan has been developed to enable the safe use of zypadhera in patients, including the management of those patients who develop post-injection delirium and sedation syndrome. in addition to mandating label language around this risk, this plan includes education and training activities to the following target audience as appr